Replimune Group Inc (NASDAQ:REPL) – Investment analysts at Wedbush issued their Q4 2019 earnings per share estimates for shares of Replimune Group in a research report issued to clients and investors on Wednesday, April 24th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.36) for the quarter. Wedbush has a “Outperform” rating and a $24.00 price target on the stock. Wedbush also issued estimates for Replimune Group’s Q1 2020 earnings at ($0.43) EPS, Q2 2020 earnings at ($0.48) EPS and Q3 2020 earnings at ($0.55) EPS.
Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, February 14th. The company reported ($0.24) earnings per share for the quarter, meeting the consensus estimate of ($0.24).
Shares of REPL stock opened at $15.73 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 38.14 and a current ratio of 38.14. Replimune Group has a twelve month low of $8.88 and a twelve month high of $23.55.
Several institutional investors have recently bought and sold shares of the stock. Northern Trust Corp boosted its stake in shares of Replimune Group by 2.5% in the fourth quarter. Northern Trust Corp now owns 81,234 shares of the company’s stock valued at $813,000 after buying an additional 2,014 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new stake in shares of Replimune Group in the first quarter valued at approximately $38,000. Bank of New York Mellon Corp boosted its stake in shares of Replimune Group by 21.2% in the fourth quarter. Bank of New York Mellon Corp now owns 24,049 shares of the company’s stock valued at $240,000 after buying an additional 4,209 shares in the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Replimune Group in the fourth quarter valued at approximately $65,000. Finally, Geode Capital Management LLC boosted its stake in shares of Replimune Group by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 52,687 shares of the company’s stock valued at $526,000 after buying an additional 6,878 shares in the last quarter. Hedge funds and other institutional investors own 57.38% of the company’s stock.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Featured Story: Consumer Price Index (CPI)
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.